mTOR: on target for novel therapeutic strategies in the nervous system
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mammalian target of rapamycin (mTOR), the key component of the protein complexes mTORC1 and mTORC2, plays a critical role in cellular development, tissue regeneration, and repair. mTOR signaling can govern not only stem cell development and quiescence, but also cell death during apoptosis or autophagy. Recent studies highlight the importance of both traditional and newly recognized interactors of mTOR, such as p70S6K, 4EBP1, GSK-3β, REDD1/RTP801, TSC1/TSC2, growth factors, wingless, and forkhead transcription factors that influence Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, tuberous sclerosis, and epilepsy. Targeting mTOR in the nervous system can offer exciting new avenues of drug discovery, but crucial to this premise is elucidating of the complexity of mTOR signaling for robust and safe clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 1×
“Inhibiting mTOR activity with the agent rapamycin can increase the autophagic clearance of proteins with long polyglutamine or polyalanine expansions [91], attenuating huntingtin accumulation and cell death in cell models of HD and protecting against neurodegeneration in fly and murine models [92].”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
Jung, C. H., Jun, C. B., Ro, S.-H., Kim, Y.-M., Otto, N. M., Cao, J., Kundu, M., & Kim, D.-H. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1249 · Cited by 2,025 · cited 5×
“mTOR can phosphorylate the mammalian homologue of Atg13 (autophagy related gene 13) and the mammalian Atg1 homologues ULK1 (UNC-51 like kinase 1) and ULK2 to prevent the progression of autophagy [77].”
BackgroundInfluentialTermination of autophagy and reformation of lysosomes regulated by mTOR
Yu, L., McPhee, C. K., Zheng, L., Mardones, G. A., Rong, Y., Peng, J., Mi, N., Zhao, Y., Liu, Z., Wan, F., et al. (2010) · Nature · doi:10.1038/nature09076 · Cited by 1,544 · cited 2×
“re-activation of mTOR appears to be required to continue with autophagy, so long as elevated levels of mTOR activity do not eventually lead to a blockade of autophagy [75].”
BackgroundInoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · cited 2×
“mTORC1 and mTORC2 can inhibit Deptor expression [16], but in some forms of cancer, Deptor expression is necessary for Akt signaling [16, 17].”
BackgroundSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 3×
“Nevertheless, chronic diseases, such as AD, may benefit from the inhibition of mTOR to allow the progression of autophagy [60].”
Background
Cited by
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Fields, C. R., Bengoa-Vergniory, N., & Wade-Martins, R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00299 · Cited by 328
Dry Age-Related Macular Degeneration: Mechanisms, Therapeutic Targets, and Imaging
Bowes Rickman, C., Farsiu, S., Toth, C. A., & Klingeborn, M. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12757 · Cited by 282
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Moors, T. E., Hoozemans, J. J. M., Ingrassia, A., Beccari, T., Parnetti, L., Chartier-Harlin, M.-C., & van de Berg, W. D. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0154-3 · Cited by 278
Activation of mTOR: a culprit of Alzheimer’s disease?
Cai, Z., Zhou, Y., Xiao, M., Yan, L.-J., & He, W. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75717 · Cited by 161
Yang, F., Chu, X., Yin, M., Liu, X., Yuan, H., Niu, Y., & Fu, L. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.02.005 · Cited by 136
mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse
Neasta, J., Barak, S., Hamida, S. B., & Ron, D. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12725 · Cited by 114
Wei, Y.-N., Hu, H.-Y., Xie, G.-C., Fu, N., Ning, Z.-B., Zeng, R., & Khaitovich, P. (2015) · Genome Biology · doi:10.1186/s13059-015-0608-2 · Cited by 117
“Moreover, aberrant control of the PI3K-Akt regulatory axis or overactivation of mTOR has been suggested to play a causal role in many aging-related disorders, including cancer, type 2 diabetes mellitus, heart disease and neurodegeneration [50,55,56].”
BackgroundThe Regulation of microRNAs in Alzheimer's Disease
Kou, X., Chen, D., & Chen, N. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00288 · Cited by 112
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Dysregulation of mitochondrial and proteolysosomal genes in Parkinson’s disease myeloid cells
Navarro, E., Udine, E., Lopes, K. D. P., Parks, M., Riboldi, G., Schilder, B. M., Humphrey, J., Snijders, G. J. L., Vialle, R. A., Zhuang, M., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00110-x · Cited by 57
The activation of autophagy protects neurons and astrocytes against bilirubin-induced cytotoxicity
Qaisiya, M., Mardešić, P., Pastore, B., Tiribelli, C., & Bellarosa, C. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.09.056 · Cited by 35
Lago, S. G., Tomasik, J., van Rees, G. F., Ramsey, J. M., Haenisch, F., Cooper, J. D., Broek, J. A., Suarez-Pinilla, P., Ruland, T., Auyeug, B., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0123-4 · Cited by 30
Dastidar, S. G., Pham, M. T., Mitchell, M. B., Yeom, S. G., Jordan, S., Chang, A., Sopher, B. L., & La Spada, A. R. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0940-20.2020 · Cited by 27
Metadata
- Authors
- Maiese, K., Chong, Z. Z., Shang, Y. C., & Wang, S.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 19
- Issue
- 1
- Pages
- 51-60
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2074866669
- Cited by
- 223
- References
- 28
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.